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Abstract
Aim: To delineate the neurogenetic profiles of brain degeneration patterns in myotonic 
dystrophy type I (DM1).
Methods: In two cohorts of DM1 patients, brain maps of volume loss (VL) and neuropsy-
chological deficits (NDs) were intersected to large- scale transcriptome maps provided by 
the Allen Human Brain Atlas (AHBA). For validation, neuropathological and RNA analyses 
were performed in a small series of DM1 brain samples.
Results: Twofold: (1) From a list of preselected hypothesis- driven genes, confirma-
tory analyses found that three genes play a major role in brain degeneration: dystro-
phin (DMD), alpha- synuclein (SNCA) and the microtubule- associated protein tau (MAPT). 
Neuropathological analyses confirmed a highly heterogeneous Tau- pathology in DM1, 
different to the one in Alzheimer's disease. (2) Exploratory analyses revealed gene clus-
ters enriched for key biological processes in the central nervous system, such as synaptic 
vesicle recycling, localization, endocytosis and exocytosis, and the serotonin and dopa-
mine neurotransmitter pathways. RNA analyses confirmed synaptic vesicle dysfunction.
Conclusions: The combination of large- scale transcriptome interactions with brain imag-
ing and cognitive function sheds light on the neurobiological mechanisms of brain degen-
eration in DM1 that might help define future therapeutic strategies and research into this 
condition.
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INTRODUC TION
Myotonic dystrophy type 1 (DM1) is a complex multisystem disease that 
affects skeletal muscles,1 heart,2 lungs,3 endocrine system,4 regulation 
of sleep cycles 5 and other aspects of brain activity.6 Epidemiologically, 
DM1 is the most common adult- onset muscular dystrophy in humans, 
with a reported prevalence of 1/7,400 people worldwide7 and is about 
three times higher in Gipuzkoa,8 Northern Spain (where this study was 
performed). Neuroimaging studies have shown the brain damage in 
DM1 patients, including grey matter (GM) atrophy mainly affecting the 
frontal and parietal lobes9 but also, in the hippocampus10 and other 
subcortical structures.11 White matter tract alterations (WM- TAs) 
have been widely reported in DM1, in both cross- sectional12– 20 and 
longitudinal studies.21 These indicate widespread WM- TA throughout 
the whole brain, but that is more severe in the frontal, temporal and 
subcortical tracts. In relation to neuropsychological performance, ex-
ecutive function, attention and visuoconstruction have been shown 
significant association with WM- TA.16,22 To the date, the neurogenetic 
profiles of such patterns of WM- TA or the ones corresponding to GM 
damage have not been yet determined.
Using an approach that combines magnetic resonance imaging 
(MRI) and large- scale brain transcriptomics, we aimed here to assess 
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to what extent the structural damage in the DM1 brain represents a 
neurogenetic signature. In contrast to other neurodegenerative dis-
eases in which a large number of candidate genes are implicated, for 
example, about 700 genes in Alzheimer's disease (AD),23 DM1 is a 
monogenic disorder caused by a mutation in the gene encoding the 
myotonic dystrophy protein kinase (DMPK).24 However, although the 
disease is monogenic, its phenotype is mainly due to an abnormal ac-
tivity of the ribonucleic acid (RNA)- binding protein muscleblind- like 
1 and 2 genes (MBNL1, MBNL2) 25,26 and CUGBP which regulates the 
expression of many other genes, such as the chloride channel 1 gene 
(CLCN1) that regulates chloride conductance during muscle develop-
ment,27 the insulin receptor gene (INSR),28 the bridging integrator 1 
gene (BIN1) 29 or other genes directly related to the main symptoms 
of the condition.30 The neuropsychological profile of DM1 is mainly 
associated with cognitive difficulties including visuospatial process-
ing and executive functioning.31,32 Strikingly, the DMPK pathogenic 
genotype has also been associated with other genes that encode 
proteins implicated in brain neurodegeneration, majorly to tau de-
posits,33 but also amyloid beta (Aβ)34 or alpha synuclein.35,36 Thus, 
it is suspected that the neuropsychological deficits (NDs) and brain 
damage found in DM1 patients might present some similarities to 
those in other neurodegenerative diseases, although this issue has 
yet to be fully addressed. Therefore, despite the monogenic origin 
of DM1, the gene- to- gene interactome scales up to implicate mul-
tiple systems in the brain and body. To date, a precise association 
between the entire transcriptome and the brain neurodegeneration 
and cognitive deterioration in DM1 patients remains unexplored.
Some studies have assessed the relationship between genetics 
and structural brain alterations in DM1, confirming that the number 
of pathogenic repeats of the cytosine- thymine- guanine (CTG) triplet 
in the DMPK gene (a parameter used to quantify the molecular se-
verity of the disease) was associated with both more GM and white 
matter atrophy, and to the NDs of these patients.20,37 Here, we per-
formed an intersection analysis of neuroimaging phenotypes and 
the Allen Human Brain Atlas (AHBA) of large- scale transcriptional 
human data,38 following a similar methodology to that used previ-
ously.39– 41 Our hypothesis was that identifying the genes whose ex-
pression coincided more closely with the brain damage found in DM1 
patients, we might better understand the gene relationships associ-
ated with the brain damage that arises in this pathology. Similarly, we 
also assessed the relationship between gene transcription in specific 
anatomical regions and the brain maps of NDs in these patients.
METHODS
Participants , two cohorts
A total of N = 95 subjects were recruited to a cross- sectional study, 
35 of whom were DM1 patients who were treated at the Neurology 
Department of the Donostia University Hospital (Gipuzkoa, Spain), 
while 60 subjects participated as healthy controls (HCs). All patients 
and HCs were recruited from the vicinity of the Donostia University 
Hospital, and the two groups were matched for age, gender and edu-
cation. The imaging data from the DM1 patients and HCs were ac-
quired at two different Institutions. At one, 19 DM1 patients (mean 
age 53.3 years [SD ± 8.1 years]; 9 males, 10 females) and 29 HC 
(52.2 [±8.1] years; 12 males, 17 females) were examined and at the 
second, 16 DM1 patients (48.8 [±7.7] years; 7 males, 9 females) and 
31 HC (47.6 [±7.6] years; 14 males, 17 females). For the mean values, 
and the comparisons between groups and cohorts, see Table 1 and 
Table S1.
The DM1 patients were only included if they had molecular con-
firmation of their DM1 diagnosis, indicating the expansion from 50 
to thousands of CTG repeats in the DMPK gene.24 The diagnosis 
was obtained when patients were between 18 and 40 years old, and 
therefore categorized as adult- onset DM1, as proposed by the fourth 
Outcome Measure for Myotonic Dystrophy Type 1 (OMMYD- 4). 
Patients were excluded if at least one of the following criteria was 
met: history of a major psychiatric or somatic disorder in accordance 
with Diagnostic and Statistical Manual of Mental Disorders, fifth 
edition (DSM- V) criteria; acquired brain damage; alcohol or drug 
abuse; the presence of corporal paramagnetic devices like pacemak-
ers or metal prosthesis that might compromise the MRI studies; and 
the presence of brain abnormalities that could affect the volumetric 
analysis. HCs satisfied the same exclusion criteria but the number of 
the CTG repeats in their DMPK gene ranged from 5 to 34.24 DM1 pa-
tients were recruited from the Neuromuscular Unit in the Neurology 
Department of the Hospital Universitario Donostia, while HCs were 
recruited from their healthy relatives and general population.
Demographic , clinical and neuropsychological variables
The demographic variables of the subjects recorded were their 
age, gender and years of education. The clinical variables were the 
CTG expansion size and Muscular Impairment Rating Scale (MIRS) 
score.42 Neuropsychological variables corresponded to compos-
ite values from different cognitive domains obtained through a 
comprehensive neuropsychological evaluation performed by an 
experienced neuropsychologist who was blind to the patient's 
clinical condition (CTG expansion size and MIRS results). The neu-
ropsychological assessment included several subtests from the 
Wechsler Adult Intelligence Scale III (WAIS III),43 including: digit 
span, vocabulary, block design, object assembly, arithmetic and 
similarities. Other cognitive tests used were as follows: Stroop 
test, California Computerized Assessment Package (CALCAP), 
Raven's progressive matrices, Rey Auditory Verbal Learning Test 
(RAVLT),44 Word Fluency,45,46 Rey– Osterrieth Complex Figure test 
(ROCF) 47 and Benton's Judgement of Line Orientation.48 The pa-
tients’ raw scores were converted into standardized t values based 
on the normative scores for the Spanish population in each test. 
Finally, the different neuropsychological scores were reduced 
into six different domains: visuospatial (block design and ROCF 
copy), verbal memory (RAVLT immediate recall, RAVLT delayed re-
call, Total RAVLT), attention (digit span, STROOP word, STROOP 
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colour, simple reaction time (RT), election RT, Sequential 1 RT, 
Sequential 2 RT), executive functioning (total RAVEN, semantic 
fluency, phonemic fluency, STROOP colour- word, STROOP inter-
ference), visual memory (ROCF delayed recall), and intelligence 
(estimation of IQ was based on vocabulary, block design, object 
assembly, arithmetic and similarities subtests).
MRI acquisition and pre- processing
For the first cohort, MRI was conducted on a 3 Tesla scanner (TrioTim, 
Siemens) using a high- resolution 3D sequence of magnetization- 
prepared rapid acquisition with gradient echo (MPRAGE) and apply-
ing the following parameters: Sagittal 3D T1 weighted acquisition, 
repetition time (TR) = 2,300 ms, echo time (TE) = 2.86 ms, inversion 
time = 900 ms, flip angle =9°, matrix = 192 × 192 mm2, slice thick-
ness = 1.25 mm, voxel dimensions = 1.25 × 1.25 × 1.25 mm3, number 
of signals averaged (NSA) = 1, slices = 144, no gap, total scan dura-
tion = 7 min and 22 s. Diffusion- weighted images were acquired using 
an echo planar imaging (EPI) sequence: 1.75 × 1.75 × 2 mm voxels; 77 
axial slices; b value of 1,000 s/mm2; 64 direction diffusion- weighted 
and 1 baseline image; TR = 10,000 ms, TE = 92 ms; angle 90, acquisi-
tion matrix size = 122 × 122.
For the second cohort, MRI was conducted on a 1.5 Tesla scan-
ner (Achieva Nova, Philips), using a high- resolution volumetric turbo 
field echo (TFE) sequence with the following parameters: Sagittal 
3D T1 weighted acquisition, TR = 7.2 ms, TE = 3.3 ms, inversion 
time = 0 ms, flip angle =8°, matrix = 256 × 232 mm2, slice thick-
ness = 1 mm, voxel dimensions = 1 × 1 × 1 mm3, NSA = 1, slices = 160, 
no gap, total scan duration = 5 min and 34 s. Diffusion- weighted im-
ages were acquired using a single shot spectral presaturation with 
inversion recovery (SPIR): 1.75 × 1.75 × 2 mm voxels; 60 axial slices; 
b value of 800 s/mm2; 32 direction diffusion- weighted and 1 base-
line image; TR = 9,967 ms, TE = 66 ms; angle 90, acquisition matrix 
size = 128 × 128.
To perform voxel- based GM morphometric comparisons be-
tween the subjects, DM1 and HCs, we performed voxel- based 
morphometry (VBM) following a procedure similar to that used 
previously,49,50 an optimized VBM protocol51 carried out with the 
FSL v6.01 software. First, skull removal was performed, followed by 






Age, years 53.30 (8.09) 48.75 (7.72) 1.69 0.10 0.57
Males, n (%) 9 (47.37) 7 (43.75) 0.05a  0.83 −0.07
Education, years 16.37 (4.87) 13.75 (4.85) 1.59 0.12 0.54
Clinical
N 19 16
CTG expansion size 522.79 
(448.44)
827.13 (433.08) −2.03 0.05 −0.69
MIRS 2.47 (0.96) 3.53 (0.83) −3.37 0.002 −1.17
Time between MRI 
and CTG measures, 
years
0.14 (0.14) 9.40 (7.23) −5.6 0.000 −1.93
Neuropsychological
N 18 16
Visuospatial −0.35 (1.21) −1.17 (1.34) 1.86 0.07 0.64
Verbal memory −0.04 (2.33) −0.74 (1.99) 0.94 0.36 0.32
Attention −2.50 (1.92) −2.62 (2.14) 0.19 0.85 0.06
Executive functioning −0.91 (2.08) −1.84 (2.40) 1.21 0.23 0.42
Visual memory −0.34 (0.97) −1.01 (1.14) 1.83 0.08 0.64
Intelligence (IQ) 101.11 
(11.51)
91.19 (13.61) 2.3 0.03 0.79
Note: Mean values (standard deviations in brackets) of the different variables separated by cohort. 
The neuropsychological variables coincide with the different composite- scores from the different 
cognitive domains. All the neuropsychological variables were calculated using normative data from 
a healthy Spanish population. All domains are represented in Z scores (Mean =0; SD =1) except IQ 
(Mean =100; SD =15). Smaller values indicate worse performance. Bold values indicate p < 0.05.
aFor gender differences, the χ2 test was used.
TA B L E  1  Demographic, clinical and 
neuropsychological variables
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GM segmentation and registration to the MNI 152 standard space 
using non- linear registration.52 The resulting images were averaged 
and flipped along the x- axis to create a left- right symmetric, study- 
specific GM template. Second, all native GM images were non- 
linearly registered to this study- specific template and ‘modulated’ 
to correct for local expansion (or contraction) due to the non- linear 
component of the spatial transformation. The modulated GM images 
were then smoothed with an isotropic Gaussian kernel at sigma = 3, 
and finally, the partial GM volume estimates normalized to the sub-
ject's head size were compared.
WM- TA were assessed with tract- based spatial statistics (TBSS) 
from FSL53 using fractional anisotropy (FA) images. First, all individ-
ual FA images were normalized to a common template using a non- 
linear transformation. Next, the mean image across all subjects was 
computed and skeletonized to get the mean FA skeletons, which rep-
resent regions with high confidence bundles common to all subjects, 
thus removing some of the individual subject- specific tract- based 
heterogeneities. FA images for each subject were then projected 
onto the mean skeleton.
Imaging statistical analysis
For the VBM analyses, a generalized linear model was fitted for each 
voxel and image using the FSL software, controlling for age and head 
size with two different contrasts: DM1 < HC and DM1 > HC. All the 
results were obtained with two- tailed tests, correcting for multiple 
comparisons using the Monte Carlo simulation cluster- wise correc-
tion implemented in the AFNI v19.3.00 software, and using 10,000 
iterations to estimate the probability of false positive clusters with a 
p value < 0.05. Each cohort was analysed separately and in combina-
tion, as explained below, although statistical comparisons between 
the two cohorts were not performed.
For the TBSS analyses, group comparison was performed using 
the randomise tool in FSL, a nonparametric permutation test for find-
ing significant statistical differences between groups at the voxel 
level. For multiple comparison correction, we used threshold- free 
cluster enhancement (TFCE)54 with a number of iterations of 5,000 
and family- wise error (FWE) corrected p = 0.05, thus ensuring that 
the chance of false positives is no more than 5%, or equivalently, en-
suring 95% confidence of no false positives. Group comparison was 
performed using two different contrasts, DM1 > HC and HC > DM1.
Transcriptomics brain maps
To build brain maps of transcription, we took advantage of the 
publicly available data from the AHBA (http://human.brain - map.
org/).38 The dataset consisted of MRI images and a total of 58,692 
microarray- based transcription profiles of about 20,945 genes sam-
pled over 3,702 different regions across the brains of six humans. 
Of the total 3,702 sampling sites, 2,728 were located in cortical and 
subcortical GM, 368 in the cerebellum, 586 in the brain stem, and 
15 in white matter. Our analyses here are restricted to the 2,728 
sites covering the cortical and subcortical GM. To pool all the tran-
scription data into a single brain template, we followed a similar 
procedure to that employed elsewhere.55 First, to re- annotate the 
probes to genes we made use of the re- annotator toolkit.56 Second, 
we removed those probes with insufficient signal by looking at the 
sampling proportion (SP), which was calculated for each brain as the 
ratio between the samples with a signal greater than the background 
noise divided by the total number of samples. Probes with a SP lower 
than 70% in any of the six brains were removed from the analysis, 
thereby ensuring sufficient sampling power in all the brains. After 
that, we chose the value of the probe for each gene with the maxi-
mum differential stability (DS), accounting for the reproducibility of 
gene expression across brain regions and individuals, and calculated 
using spatial correlations similar to those employed previously.57 For 
this the automated anatomical labelling (AAL) atlas was used58 from 
which the cerebellum was excluded, resulting in 90 different ana-
tomical regions.1 Finally, to remove the intersubject differences, the 
transcription values for each gene and brain were transformed into 
Z scores and pooled together from the six different brains, obtain-
ing a single map using the MNI coordinates provided in the dataset. 
Finally, to eliminate the spatial dependencies of the transcription 
values at the sampling sites (that is, to correct for the fact that near-
est sites have more correlated transcription), we finally obtained a 
single transcription value for each region in the AAL atlas by cal-
culating the median of all the values belonging to the given region.
Association between VL and transcriptomics
Volume loss (VL) was defined as the t statistic resulting from the 
group comparison DM1 < HC. To associate VL with transcriptom-
ics, we transformed the t statistics map to the same AAL atlas as 
that used for the transcription values, calculating the median of the 
t statistics between all values in each region. For each gene, we cal-
culated a similarity index using the Pearson correlation coefficient 
between VL and transcriptomics, the two variables represented in 
vectors with a dimension equal to the number of regions in the atlas. 
Therefore, a high contribution to this association is to have a high 
value in the product of the two vector components for a given re-
gion. In addition, the similarity index (i.e., spatial correlation) is pro-
portional to the sum of all product terms across all brain regions, 
thus capturing systematically similar patterns throughout the brain 
of the gene expression vector and the one for VL. This procedure 
was done separately for the two cohorts.
Association between NDs and transcriptomics
For the association between NDs and transcriptomics, we first 
built brain maps of ND using the BrainMap meta- analysis platform 
(http://www.brain map.org/). In particular, the Sleuth tool v3.0.359 
was used to search all the papers in the database using the name of 
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each neuropsychological domain as a keyword. In this way, all the 
co- activation coordinates that resulted from studies based on func-
tional imaging when the participant in the scanner was performing 
a task related to each neuropsychological domain were obtained. 
Next, the GingerAle tool v3.0.260 was used to pool all the coordi-
nates onto a single co- activation brain map for each neuropsycho-
logical domain, representing these as a Z score after applying the 
activation likelihood estimation (ALE) method. The brain maps were 
then transformed to the same AAL atlas by calculating the median of 
all the Z scores belonging to the same region in the atlas. Finally, the 
association between ND and transcriptomics was assessed for each 
gene through the similarity index, equivalent to the Pearson cor-
relation coefficient between ND and transcriptomics; the two vari-
ables were represented in the vectors with a dimension equal to the 
number of regions in the atlas. Transcriptomics correlates were only 
obtained for those neuropsychological domains that were most af-
fected, identified by choosing a mean Z score < −2, previously stand-
ardized to the normative scores based on a Spanish population. This 
procedure was done separately for the two cohorts.
DM1 relevant genes and GO
Relevant genes were identified by combining the results from two 
different strategies. The first one was confirmatory, a hypothesis- 
driven strategy (HDS) that involved reviewing previous studies to 
identify genes that play a relevant role in some neurobiological as-
pects of DM1 (Table S2). The second was exploratory, a data- driven 
strategy (DDS) consisting of identifying the genes with the strongest 
transcription correlation with the parameter of interest, either VL or 
ND. In particular, we chose those genes with similarity index values 
where z < −2 or z > 2, i.e., outliers of the correlation distribution in 
both the negative and positive tails. Genes in the positive tail (z > 2) 
were designated as pos- corr genes (P), whereas those in the negative 
tail (z < −2) were considered neg- corr genes (N). For example, when 
assessing the VL, the P genes were systematically expressed more 
strongly than other genes in the brain regions with more pronounced 
atrophy, whereas the N genes were expressed much more weakly 
than the rest. Although this procedure was performed separately for 
the two cohorts, the P and N genes finally adopted were those pre-
sent in the two cohorts. We also considered those genes that were 
expressed similarly to the P and N genes as relevant genes, which 
were dubbed connector hubs (C). To identify these, we made use of 
the ‘gene- expression connectivity matrix’ that represents the simi-
larity in expression between gene pairs obtained from the Pearson 
pairwise correlations for each entry.2 For those genes absent in the 
groups of P and N genes, the strength towards the two P and N tails 
was calculated separately. PC genes were identified as those genes 
with a Z score in connectivity strength towards the P tail >2, and simi-
larly, NC genes were identified by having a Z score in the strength to-
wards the N tail >2. For the hypothesis- driven genes given in Table S2 
that were defined as P or N genes, their statistical significance was 
assessed by surrogate data testing. The BrainSMASH tool61 was used 
to build null- distributions by generating 10,000 random maps with 
the same spatial autocorrelation as that for VL or ND.
Finally, we pooled together all the relevant genes (P genes, N 
genes, PC genes, NC genes and the genes that were common to 
PC and NC) to perform unsupervised K- means clustering with the 
Silhouette strategy to identify the optimal number of clusters. For 
each cluster, we performed a gene ontology (GO) biological pro-
cess62 and Reactome pathways63 overrepresentation test using 
PANTHER v15.0 (http://panth erdb.org/), with the entire Homo 
Sapiens genome as the reference list and applying a Fisher's exact 
test with Bonferroni correction (p < 0.05). To make the data more 
readily interpretable, we only reported ≥2- fold enrichment.
Neuropathological analyses
Human brain samples were collected from DM1 patients after 
approval of the local ethical committee, treated and stored fol-
lowing the guidelines of the Spanish legislation (Real Decreto de 
Biobancos RD1716/2011; see Supplementary Material for a de-
tailed protocol).
Brain samples were analysed from seven DM1 patients with ages 
60, 58, 74, 67, 58, 68 and 59 at death. All of them were diagnosed by 
genetically- confirmed DM1 and had clinical manifestations. Due to 
the external origin of the cases, not all brain regions were available 
for study in every case; in some cases, only 20 different areas were 
suitable for the neuropathological study. Although frozen samples 
were obtained from different regions, only the hippocampus was 
available in every case for biochemical studies.
Gene expression was analysed in the hippocampus of four cases 
with neurofibrillary tangles (NFT) pathology stages III– VI of Braak 
(NFT control, aged 76, 85, 70 and 85), four middle- aged (MA) in-
dividuals (aged 53, 48, 55 and 39, and three DM1 cases [I13– 131, 
I13– 133, I13– 134], aged 67, 68, and 59, stages III– VI). The selection 
of the first group was chosen to discriminate possible alterations 
linked to NFT in DM1 which might not be present in current cases 
with NFT pathology not linked to DM1 (AD- related pathology).
RNA from hippocampus was extracted following the instructions 
of the supplier (RNeasy Mini Kit, Qiagen® GmbH, Hilden, Germany). 
RNA integrity (RIN) and 28S/18S ratios were determined with the 
Agilent Bioanalyzer (Agilent Technologies Inc, Santa Clara, CA, 
USA). RIN values were between 5.5 and 7.5. Samples were treated 
with DNase digestion, and RNA concentration was evaluated using a 
NanoDrop™ Spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA). The normality of distribution of fold- change values was 
analysed with the Kolmogorov– Smirnov test. Pearson's correlation 
coefficient was used to assess a possible linear association between 
two continuous quantitative variables. Statistical analysis of the ex-
pression data between groups was made using one- way analysis of 
variance (ANOVA) followed by Tukey post- test or Kruskal– Wallis test 
followed by Dunns post hoc test when required using the SPSS soft-
ware (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, 
Version 21.0; Armonk, NY: IBM Corp). Outliers were detected using 
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the GraphPad software QuickCalcs (p < 0.05). All data were expressed 
as mean values ± standard error of the mean (SEM). Differences be-
tween cases were considered statistically significant at *p < 0.05; 
trends were indicated with * and the exact p value.
RESULTS
A total of 35 DM1 patients and 60 HCs participated in this study, 
examined in two different cohorts at two distinct centres. In the 
F I G U R E  1  Methodological scheme for the association between transcriptomics and atrophy in DM1, measured as brain volume loss (VL). 
(A) Two cohorts of DM1 patients were recruited (orange and blue) and we obtained the brain maps of the VL for each, comparing the images 
with a group of HCs using voxel- based morphometry (VBM) and tract- based spatial statistics (TBSS), correcting for multiple comparisons. 
We aimed to characterize the association between VL and transcriptomics, assessing the similarity in the spatial patterns of VL across brain 
regions and the spatial patterns of gene transcription from the AHBA dataset, pre- processed following a pipeline that is summarized in six 
main steps (for further details, see Methods). After running the AHBA pipeline, about 14 K genes finally had transcription values used in the 
analysis from the 58- K probes originally available. The red regions in the brain correspond to the sites at which transcription was sampled. 
*Of the total 3,702 sampling sites, 2,728 were located in cortical and subcortical grey matter, 368 in the cerebellum, 586 in the brain stem, 
and 15 in white matter. Our analyses here are restricted to the 2,728 sites covering the cortical and subcortical grey matter. (B) The sampling 
proportion (SP) and differential stability (DS) for the 27 preselected hypothesis- driven genes included in the list of candidates relevant to 
DM1 (obtained by reviewing the literature). The CACNA1S, CLCN1, KL and SIX5 genes did not have a mean SP value above 70% and thus, 
they were excluded from further analyses. Of the remaining 23 genes, the maximum DS corresponded to SNCA and the minimum DS to 
DMPK (see arrows). By examining the spatial similarity in the transcription values, the remaining 23 candidate genes were clustered into 
three groups. The blue one formed by DMD, SNCA and MAPT played a major role in the characterization of VL
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first of these, 19 DM1 patients were recruited (9 males) with 
an average age of 53.3 years (range 42.1– 69.5 years) and with 
16.4 years of education (range 8– 25 years). With respect to the 
clinical variables, these patients had an average MIRS score of 2.5 
(range 1– 4) and a mean CTG expansion of 522.8 (range 65– 1,733). 
These patients were compared with 29 well- matched HCs. In the 
second cohort, 16 DM1 patients were recruited (7 males), with an 
average age of 48.8 years (range 36.0– 61.0 years) and 13.2 years 
of education (range 6– 22 years). The mean MIRS score in this co-
hort was 3.5 (range 2– 5) and with a CTG expansion size of 827.1 
(range 267– 1,833). These patients were compared to 31 well- 
matched HCs, and all the demographic, clinical and neuropsycho-
logical variables collected in the study are detailed in Table 1 and 
S1. As explained in the Methods, the two cohorts were considered 
independently for the imaging analyses, obtaining the correspond-
ing VL brain maps and identifying the list of relevant genes for 
each cohort separately. Importantly, the two brain profiles of VL 
(represented by the vector of statistics t per brain region) had a 
high spatial correlation across brain regions (r = 0.82), thus indicat-
ing that the statistics after group comparison remain quite stable 
in the two cohorts despite MRI scanner differences, which ulti-
mately guaranteed a common list of relevant genes present in the 
two cohorts. It was this list of common genes shared by the two 
cohorts the one analysed further.
The VL brain maps from each cohort consisted of several wide-
spread cortical and subcortical regions (Figure 1A). There was bilat-
eral subcortical VL in the hippocampus, thalamus, basal ganglia and 
cerebellum, while cortical VL was evident in multiple regions that 
included part of the temporal, occipital, parietal cortices, precuneus, 
pars orbitalis and medial prefrontal cortex (for details, see Tables 
S3 and S4). Importantly, the VL maps for the two cohorts differed 
more in the cortical regions (Dice index, D = 0.3), and they were more 
similar in the subcortical ones (D = 0.8), indicating that subcortical 
atrophy was more prevalent in DM1 and less variable than cortical 
atrophy.
The WM- TA brain maps from each cohort showed alterations for 
most of the white matter tracts (Figure 1A; for significance values 
and statistics for each tract, see Tables S5 and S6). When looking 
for differences across cohorts, we found high similarity between 
the two maps (D = 0.7), indicating again that despite MRI scanner 
differences, the results of WM- TA were quite robust from the two 
cohorts.
The main steps in the pipeline were followed to analyse the 
transcriptomics through AHBA dataset (Figure 1A), providing brain 
maps of transcriptional activity for each gene that were spatially cor-
related with the brain maps of VL and subsequently, with those of 
ND. A list of the 27 most relevant hypothesis- driven genes in DM1 
was drawn up (Figure 1B; for details on references supporting the 
selection of each gene, see Table S2). Of these 27 preselected genes, 
four genes were discarded based on their SP and DS values (KL, SIX5, 
CLCN1, CACNA1S). These 4 genes had less than 70% SP (Figure 1B), 
which implied insufficient transcription signal across all the sampling 
sites. Therefore, the final list of the most relevant hypothesis- driven 
genes contained: DMPK, HSPB2, INSR, CPEB4, ANK2, ARHGEF7, 
SOS1, PHKA1, MBNL1, KIF13A, APP, MAPT, SNCA, MBNL2, RIPK1, 
PRNP, TARDBP, MAP3 K7, BIN1, DMD, LDB3, TTN and CAPN3. When 
the pairwise gene- to- gene similarity in transcription was evaluated 
across the brain for these 23 genes, Silhouette maximization identi-
fied three clusters (in yellow, blue and green in Figure 1B), indicative 
of functional similarities in the transcription signals among the 23 
most relevant genes.
We next applied a DDS that involved identifying the genes from 
the entire transcriptome with maximal association in the VL maps, 
resulting in a total of 370 N genes and 187 P genes from the first 
cohort and 441 N- genes and 161 NP- genes from the second one. 
The genes common to the two cohorts were those finally used in 
the analysis, a total of 251 N genes and 101 P genes (Figure 2A). 
Interestingly, two of the genes in the list of the 23 most relevant 
hypothesis- driven genes also appeared in the list of N genes, SNCA 
and DMD, displaying a similar transcription pattern as the MAPT 
gene (blue cluster in Figure 1B). The spatial correlation of SNCA and 
DMD transcription with the amount of VL in the different brain re-
gions proved to be negative for the two genes and smaller in the 
two cohorts: < −0.52 for DMD and < −0.70 for SNCA (Figure 2B 
and Table S7). In addition to identifying the N and P genes, we also 
searched for the NC and PC genes (Figure 3A) that represent hubs 
towards the N and P tails of the expression similarity matrix. We 
found 452 NC genes, 396 PC genes and 238 genes connecting both 
N and P tails. Remarkably, in the group of PC genes, we found LDB3, 
CAPN3 and HSPB2 that were in the list of hypothesis- driven genes, 
belonging to the same cluster of expression similarity (green cluster, 
Figure 1B). In addition, the preselected gene PHKA1 was also com-
mon to the groups of NC and PC genes.
Pooling the N, P, NC and PC genes together, along with those 
common to both the NC and PC categories, we adopted a DDS to 
achieve unsupervised clustering of the expression similarity matrix, 
identifying two major clusters after Silhouette maximization (in blue 
and red in Figure 3B). Importantly, the N and P genes fully segre-
gated into the two differentiated clusters, with all the N genes be-
longing to the blue cluster and all the P genes to the red one, thereby 
confirming the different functional roles of the groups of genes in 
the N and P tails. These two clusters were used separately for gene 
enrichment analysis (the list of genes included in each cluster are 
given in Tables S8 and S9). The search for the GO biological processes 
and Reactome pathways confirmed the differentiated roles of these 
two clusters, with the neg- corr genes more related to neuronal and 
synaptic function, involving key synaptic vesicle events such as recy-
cling, localization, endocytosis and exocytosis but also, the dynamics 
of serotonin and dopamine neurotransmitter release (Figure 3C). By 
contrast, the cluster of pos- corr genes was more related to non- 
neuronal activities, such as interferon signalling, endothelial cell 
differentiation, angiogenesis, blood transport and cell development.
To assess how the transcriptomics correlated with ND, we 
focused on the neuropsychological domains in which the com-
posite score reflected strong impairment, satisfying z < −2, which 
was only the case for the attention category (first cohort z = −2.5, 
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second cohort z = −2.62: see Table 1 and Figure 4A for the distribu-
tion of all the Z score values from the two cohorts). As indicated in 
the Methods, the attention composite was obtained by averaging 
the Z scores for the following domains: digit span, STROOP word, 
STROOP colour, simple RT, election RT, sequential 1 RT and sequen-
tial 2 RT.
We then obtained brain co- activation maps using ‘Attention’ as 
a keyword for the search in GingerAle (Figure 4B). As for VL, we cal-
culated the association between the attention co- activation maps 
and transcriptomics by calculating the spatial Pearson correlation 
between the two Z score vectors (one value per brain region in the 
atlas, see the histogram of all the correlations in Figure 4C). There 
was a total of 217 N genes (including SNCA), 54 P genes, 336 NC 
genes (including MAPT from the list of preselected hypothesis- 
driven genes), 265 PC genes, and 156 genes common to both the 
NC and PC gene sets (including PHKA1). Pooling together all classes 
of genes, we followed a DDS of unsupervised clustering and iden-
tified two clusters after Silhouette maximization (Figure 4C, Tables 
S10 and S11). Like VL, the two clusters were highly segregated and 
incorporated all neg- corr genes in one cluster, which was enriched in 
genes related to neuronal and synaptic function (Figure 4D), with all 
the pos- corr genes in the other cluster enriched in non- brain- related 
activities.
To validate some of the predictions done by our computational 
strategy linking neurodegeneration and neuropsychology with 
transcriptomics, we also performed neuropathological analyses 
of brain samples from DM1 patients. Neuropathological details of 
the cases are shown in Table 2. Overall, moderate cerebral atrophy 
with enlarged ventricles was found in every DM1 case. The main 
common microscopical alterations were pre- tangles, neurofibril-
lary tangles, and neuropil threads in selected regions of the brain 
stem and cerebrum. NFTs were stained with antibodies AT8 (P- tau 
Ser202/Thr205), P- tau ThR181, P- tau Ser422, 3Rtau, and 4Rtau. 
The distribution was variable depending on the case. Cases I09- 
254 and I13- 132 were categorized as stages I/II of Braak; cases 
I09– 255, I13– 131, and I13– 134 as stages III/IV; and cases I09– 256 
and I13– 133 as stages V/VI. β- amyloid deposition was absent in 
five cases, and present in cases I13– 134 and I13– 133 correspond-
ing to Thal phases 1 and 3, respectively. Mild astrocytic gliosis 
and microgliosis were observed in the same regions with NFTs. 
Dystrophic neurites, reactive astrocytes and active microglia were 
found around β- amyloid deposits in senile plaques. Lewy bodies 
were found in one case (I13– 133) corresponding to stage 3 of 
Braak of Parkinson's pathology. TDP- 43 proteinopathy was ab-
sent in every case. Mild to moderate small blood vessel disease, 
characterized by artheriolosclerosis and arteriolar hyalinosis, was 
F I G U R E  2  Data- driven strategy to determine the association between the transcriptome and VL in DM1. (A) Histogram of the spatial- 
correlation values (measured as the Z- score) between volume loss (VL) and transcriptional activity for all the genes in both cohorts. For both 
cohorts the N genes (z < −2) and P genes (z > 2) are coloured in blue and red, respectively. The final list of genes used for further analyses 
are those that are common to the two cohorts, consisting of 251 N genes and 101 P genes. From all the genes that provide a maximum 
association between VL and transcriptomics (Tables S6 and S7), only two genes were in the panel of preselected genes: SNCA and DMD. (B) 
Brain maps of transcription in the brain regions for the two genes DMD and SNCA, which provided a high spatial correlation (r) with the VL 
brain maps for both cohorts
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common. This was accompanied by mild status cribosus in the stri-
atum, thalamus and white matter in four cases. The white matter 
of the cerebrum was reduced in size and showed mild to moderate 
myelin pallor in five cases (I09– 255, I13– 131, I13– 132, I13– 133 
and I13– 134); the corpus callosum was thinner. Myelin changes, 
as seen with Klüver– Barrera were accompanied by loss of nerve 
fibres as visualized with anti- neurofilament antibodies. Axonal 
ballooning was absent. No inflammatory changes were observed 
in the white matter, with the exception of a few pigment- laden 
perivascular macrophages. Corpora amylacea were seldom ob-
served in the subventricular region, perivascular spaces and sub-
pial parenchyma. One case had suffered from a recent infarction 
in the left occipital cortex. Three cases had mild Purkinje cell loss 
(I13– 131, I13– 132 and I13– 133), and two had mild atrophy of the 
inferior olives accompanied by astrocytic gliosis; representative 
tau pathology in Figure 5 lower panel.
Western blots of sarkosyl- insoluble fractions stained with anti- 
Tau- P- Ser214 antibodies revealed three bands of 68 kDa, 64 kDa, 
60 kDa and an upper band of 73 kDa in one case with AD stage V. This 
pattern was in striking contrast with DM1 cases I09– 254, I09– 255 and 
I09– 256 processed in the same membrane that apparently showed 
two main bands of 58 and 55 kDa united by a smear, and no bands of 
upper molecular weights. The incubation of other membranes with 
anti- 4Rtau and anti- 3Rtau showed similar alterations. Unique bands 
of low molecular between 50 and 60 kDa were in striking contrast 
with the bands between 60 and 70 kDa observed in AD. Next, the 
seven cases with DM1 were run in the same gel and blotted with anti- 
P- tau- Ser214 antibodies. Two bands of 58 and 55 kDa characterized 
cases I09– 255 an I09– 256; one band of about 59/60 kDa charac-
terized case I09– 254. However, four bands of about 64, 60, 58 and 
55 kDa were obtained in cases I13– 131, I13– 132 and I13– 134. Finally, 
an additional band of about 68 kDa and bands of molecular weight 
below 50 kDa were identified in case I13– 133. In agreement with 
the different phospho- tau bands depicted with the antibody P- tau- 
Ser214, the blots using anti- 4Rtau and anti- 3Rtau equally disclosed 
individual patterns of bands particularly linked to 3Rtau. Biochemical 
details of tau bands in every case are shown in Table 2; representative 
Western blots in Figure 5 upper panel.
We also studied the expression of selected genes from hippo-
campal tissue from DM1 patients. The study of messenger- RNA 
(mRNA) levels of genes related to synaptic vesicles revealed down- 
regulated expression of SNAP25 (p = 0.035) and a trend to reduced 
F I G U R E  3  Functional description of the genes with the highest association with volume loss (VL). (A) An all- to- all gene- expression 
similarity matrix identified the connector hub genes. A total of 1,086 genes were found, equal to the sum of the NC =452 (blue), PC =396 
(red) and 238 common NC and PC genes (grey). (B) Two clusters were finally found that pooled all gene classes, the blue one contains the 
original N = 251 genes and the red one containing the original p = 101 genes. (C) Gene enrichment for GO biological process and Reactome 
pathways: in blue are the neg- corr genes and in red, the pos- corr genes. Abbreviations: Act., activation; CNS, central nervous system; Mod., 
modulation; Neg., negative; Pos., positive; Rec., receptor/s; Reg., regulation
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expression of SYP and SYN1 (p = 0.06 and p = 0.08, respectively) 
between DM1 and NFT cases. Regarding the expression of genes re-
lated to structural components of synapse, HOMER1 mRNA was sig-
nificantly reduced in NFT cases compared with MA (p = 0.037). PCLO 
and ABLIM2 showed a tendency to decrease (p = 0.07 and p = 0.07, 
respectively) in NFT cases compared with MA cases. None of this 
group of genes was altered in DM1. The study of the expression of 
GABAergic- and glutamatergic- related genes showed significantly 
reduced levels of GABRD transcript in NFT cases when compared 
with MA (p = 0.05) and a tendency to reduced expression of GABRG2 
in NFT cases compared with MA (p = 0.10) and DM1 cases (p = 0.09) 
(Figure 6). Very striking, from the genes analysed in Figure 6, genes 
SNCA, SNAP25, SYP, SYN1, SLC17A7 (from synaptic vesicles; panel A), 
FRMPD4, PCLO, BSN, ARPC5L (from synapse structural components; 
panel B), and GABRA3, GRIA1 (from GABAergic- and glutamatergic- 
related genes; panel C), all of them appears in the neg- corr gene list 
used in the enrichment obtained after linking VL or ND with tran-
scriptomics (Table S8). The tendency showed in Figure 6 of this set 
of genes is to be downregulated with respect to MA and NFL, in 
agreement with the negative- association of these genes with VL.
DISCUSSION
The AHBA provides information on the transcriptome across the 
brain in unprecedented detail, covering about 3,702 sampling sites 
and allowing activity patterns to be built for about 20,500 genes as a 
specific signature for each anatomic region. To date, its use has shed 
light on several fundamental aspects of the brain and their association 
with the transcriptome, such as myelination,64 hierarchical cortical 
organization,65 visuomotor integration 41 or large- scale connectiv-
ity.39,66,67 In addition, it has provided data regarding pathologies, 
F I G U R E  4  Data- driven strategy to define the association between the transcriptome and attention co- activation maps in DM1. (A) 
Attention scores measured as Z- scores for the two cohorts. Because the Z- scores were normalized to the values in the HCs, negative values 
of z indicate worse performance than the HCs. (B) Attention co- activation maps built with the GingerALE tool and projected onto the atlas. 
(C) Histograms of the spatial correlations between the Z scores of the attention maps and the transcriptional activity for each gene. The 
tail of N genes (z < −2, coloured in blue) includes the SNCA gene from the list of preselected genes, whereas the tail of the P genes (z > 2, 
red) does not include any of these. Following a procedure similar to that described in Figure 3A, we identified the PC genes (red), NC genes 
(blue, including MAPT), and those common to the NC and PC (grey, including PHKA1). (D) After pooling all classes of genes together and 
clustering, two groups were defined: one including all the neg- corr genes (blue, with SNCA and MAPT) and one with the pos- corr genes (red, 
with PHKA1). Gene enrichment for the tags GO biological process and Reactome pathways. As in Figure 3C, the two clusters also represented 
two separated functions: the neg- corr one correlated with neuronal functions, while the pos- corr correlated to non- brain functions. 
Abbreviations: Mod., Modulation; Neg., Negativek; Pos., Positive; Reg., Regulation
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suggesting novel molecular mechanisms underlying some disor-
ders, such as autism spectrum disorder 68 or functional neurologi-
cal disorder.69 It is important to emphasize that our methodology, 
assessing the relationships between brain images associated with 
neurodegeneration and the entire transcriptome is complemen-
tary to other techniques, such as genome- wide association studies 
(GWAS),70 simultaneously addressing genotype– phenotype associa-
tions from hundreds of thousands to millions of genetic variants in a 
data- driven manner. However, it is also important to note that such 
a vast number of multiple comparisons require very large samples to 
achieve statistical power, which is an important limitation for mono-
genic disorders like DM1.
Monogenic disorders are paradigmatic disease models of neu-
rogenetic origin, whereby a mutation in a single gene can cause the 
disease. However, the alterations causing DM1 appear to propa-
gate systemically to a larger proportion of the gene- to- gene inter-
actome, affecting the function of several other genes. Here, we 
adopted a novel approach using the AHBA to study the transcrip-
tomic correlates of brain damage and ND in DM1 patients, which to 
our knowledge has yet to be addressed. Our first finding is related 
precisely to the mutation located in the un- translated region of the 
DMPK gene, which triggers the disease and that we found to have 
the lowest DS (0.19) among the panel of the 23 hypothesis- driven 
preselected genes. Thus, DMPK expression was less reproducible in 
different brain regions and individuals, and consequently, it was more 
poorly enriched in terms of brain- related biological processes.57 By 
contrast, the SNCA gene has the highest DS value (0.84). Our sec-
ond finding is related to the clusters of spatial similarity among the 
hypothesis- driven genes in DM1. In particular, we found three clus-
ters, one including the DMPK gene together with LDB3, CAPN3 and 
HSPB2, the three latter genes associated with VL in DM1 patients. 
The second cluster contains several genes with a similar expression 
to PHKA1, which was associated with VL and ND in these patients. 
Finally, the third cluster contains the genes SNCA, DMD and MAPT, 
and as we show, it plays the most relevant role in VL and ND in DM1.
In relation to DM1 and MAPT, it has been shown that the alter-
ation of Tau exon 2 splicing may produce predominant expression of 
low molecular weight Tau isoforms in DM1.71,72 This is accompanied 
by abnormal splicing of Tau exon 6 in brain but not in muscle.73 Mis- 
splicing of exon 10 has also been reported in some cases with DM1.74 
Splicing alterations of Tau in DM1 differ from those occurring during 
fetal development; mis- splicing of Tau in DM1 is resulting from a 
disease- associated mechanism.75 The most common band pattern of 
phospho- Tau in Western blots of sarkosyl- insoluble fractions is the 
presence of a reduced band of 68/69 kDa and overexpression of Tau 
55 kDa.72 An abnormal pattern of phospho- Tau is also observed in 
the present series with marked individual variability. Low molecular 
phospho- Tau isoforms of about 58 and 55 kDa, as revealed with the 
P- Tau- Ser214 antibody, are present in almost every case, and they 
are the unique bands in two cases. Another case shows a predom-
inant band of about 60 kDa. Three cases show four bands of about 
64, 60, 58 and 55 kDa. One case is characterized by five bands of 
68/69, 64, 60, 58 and 55 kDa. This is associated with variable indi-
vidual patterns of 3RTau and 4RTau isoforms in sarkosyl- insoluble 
fractions.
The exploratory strategy DDS revealed the existence of two tails 
in the distribution of spatial- similarity between transcription activ-
ity and VL or ND. The cluster containing the pos- corr genes pro-
vided an enrichment towards non- brain- related functions, mainly 
interferon signalling, endothelial cell differentiation, angiogenesis or 
blood transport, processes known to be affected in DM1.2,76– 78 Pos- 
corr genes indicated that in those brain regions where more VL or 
ND existed, the genes are systematically transcribed more strongly, 
and vice versa, in the regions where the genes are more weakly ex-
pressed, VL or ND was less pronounced. It is important to emphasize 
that the association between gene expression and imaging or neuro-
psychology has not been found within a specific brain region, but it 
takes into consideration global multivariate VL and ND brain maps. 
Therefore, our relations between VL, ND and transcriptomics are in 
this sense fully multivariate, making it difficult to sort out towards 
TA B L E  2  Neuropathological details of cases studied
case age NFT Braak
SP 
Thal LB Braak TDP−43 others
Western blotting P- tau- Ser214, 
tau bands
I09– 254 60 Stage II No No No — 58/59 kDa,
I09– 255 58 Stage IV No No No sbvd, sc, wmd, inf oliv 58 kDa, 55 kDa
I09– 256 74 Stage V No No No inf oliv 58 kDa, 55 kDa
I13– 131 67 Stage III/IV No No No sbvd, sc, wmd, Pc↓ weak 68 kDa, 64 kDa, 60 kDa, 
58 kDa, 55 kDa
I13– 132 58 Stage I- II No No No sbvd, wmd, Pc↓ 64 kDa, 60 kDa, 58 kDa, 55 kDa
I13– 133 68 Stage V/VI Thal 3 LB 3 No sbvd, sc, wmd, Pc↓ 68 kDa, 64 kDa, 60 kDa, 58 kDa, 
55 kDa, lower bands
I13– 134 59 Stage III/IV Thal 1 No No sbvd, sc, wmd, infarct 66 kDa, 64 kDa, 58 kDa, 55 kDa
Abbreviations: inf oliv: mild to moderate nerve cell loss and mild astrocytosis in the inferior olives; infarct: acute occipital infarction; LB Braak: Lewy 
body pathology according to Braak stages; NFT Braak: Braak stages of neurofibrillary tangle pathology; Pc↓: mild to moderate loss of Purkinje cells 
in the cerebellum; sbvd: small blood vessel disease (arteriolosclerosis, arteriolar hyalinosis); sc: status cribosus and dilatation of perivascular spaces; 
SP Thal: phases of senile plaques according to Thal scale; TDP- 43: TDP- 43 proteinopathy; wmd: mild to moderate demyelination of the cerebral white 
matter.
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which specific region the triple correspondence (VL, ND and genet-
ics) might converge.
The cluster containing the neg- corr genes incorporated DMD, 
MAPT and SNCA, providing instructions to produce respectively 
the proteins dystrophin, Tau and alpha- synuclein. These results 
are consistent with previous studies on DM1 patients, for in-
stance, the existence of abnormalities in dystrophin,79,80 Tau- 
positive degenerative neurites,81 in agreement with our series 
where all showed phospho- Tau tangles and recently supported 
by common molecular pathways between the DMPK and MAPT 
genes,33 and the presence of alpha- synuclein Lewy bodies,36 also 
found in one of the seven patients assessed in this study by the 
neuropathological analyses. Moreover, the enrichment of this 
cluster was towards brain- related biological activities, such as 
synaptic vesicle processes (recycling, localization, endocytosis 
and exocytosis), and serotonin and dopamine neurotransmitter re-
lease (Table S12). These findings are in agreement with previous 
work in transgenic DM1 mice (DMSXL) showing synaptic protein 
dysregulation,82,83 events mediated by RAB3A upregulation and 
SYN1 hyperphosphorylation. Importantly, the same authors in82 
validated these results from human tissues from DM1 patients. 
Here, we extend these results in a small series of three cases of 
hippocampal tissues from DM1 patients and assess the expres-
sion by RT- PCR of 22 genes related to synaptic vesicles function, 
synapse structure components and GABAergic and glutamatergic 
functions. We found down- regulated genes in DM1 more than in 
HCs (middle- aged individuals with no NFT pathology), although 
in a non- significant way, and more than in a second control group 
of AD- related pathology with similar NFT stage in a significant 
way for some of the genes such as SYP and SYN1. In relation to 
synapse structure components, our analyses have shown signifi-
cant alterations in PCLO between DM1 and AD related with similar 
NFT control group, and the same occurred for GABRG2 gene when 
looking into the function of GABAergic- and glutamatergic- related 
vesicles. Therefore, the comparison between DM1 cases and 
NFT cases linked to AD- related pathology with similar NFT Braak 
F I G U R E  5  Neuropathological analyses of brain samples revealed a high heterogeneous Tau- pathology in DM1, different to the one in AD. 
Upper panel: Gel electrophoresis and Western blotting of sarkosyl- insoluble fractions of the hippocampus incubated with antibodies against 
3Rtau, 4Rtau, and phosphorylated tau at serine 214 (P- tau- Ser214) in DM1 cases, and one AD for control. AD is characterized by three 
bands of 68, 64 and 60 kDa and an upper weak band of 73 kDa. DM1 cases are characterized by the presence of lower bands of 58 and 
55 kDa, and occasional upper bands of 60 and 64 kDa; the band of 68/69 kDa is barely present. This particular pattern, including differences 
from one case to another, is associated with low molecular weight 3Rtau and 4Rtau isoforms suggesting complex altered Tau splicing. Lower 
panel: Representative images of NFTs and neuropil threads in the entorhinal cortex (EC), CA1 area of the hippocampus (CA1), temporal 
cortex (TC), and parietal cortex (PC), visualized with the antibody AT8, and anti- 3Rtau and 4Rtau antibodies. Paraffin sections slightly 
counterstained with haematoxylin; bar =25 μm
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staging shows substantial differences. Whether these changes 
are due to different Tau species in DM1 and AD- related pathol-
ogy or to other disease- specific factors deserves further study. It 
is important to emphasize that our analyses are complementary 
to those performed in the transgenic DM1 mice.82 Although the 
animal model showed that the CTG expansion affected synaptic 
vesicle proteins, neurotransmission and behaviour, these mice did 
not have apparent Tau pathology, and therefore, synaptic alter-
ations were probably linked to CTG expansion rather than Tau. 
Our human data showed the presence of NFT in all tissues to-
gether with an aberrant synaptic vesicle dysfunction.
The major limitation of using AHBA transcriptomics data is that 
this atlas was obtained from brain samples from healthy young 
adults, and not from DM1 patients’ brain tissues, so the relations 
studied here between pathological VL or ND and healthy transcrip-
tomics still might shed some light on systemic neurological aspects. 
Indeed, our results showed the participation of some of the genes 
previously reported to play a role in the pathophysiology of DM1. 
F I G U R E  6  RNA expression in hippocampal tissues from DM1 patients revealed protein dysfunction of synaptic vesicle processes in 
DM1. mRNA expression of synapse- related genes was analysed in the hippocampus in middle- aged (MA) control cases, myotonic dystrophy 
1 (DM1) cases, and cases with neurofibrillary tangles (NFT control) linked to AD- related pathology at middle and advanced stages (III- VI) of 
Braak and Braak. (A) Synaptic vesicles coding genes. (B) Synapse structural components coding genes. (C) GABAergic- and glutamatergic- 
related coding genes. All data were expressed as mean values ± SEM. Differences between groups are statistically significant at *p < 0.05; 
trends are indicated with * and the exact p value
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Despite this limitation, we have presented here neuropathological 
analyses of brain tissues and samples from DM1 patients to confirm 
a high heterogeneity of phospho- Tau fingerprints in DM1 patients, 
together with synaptic vesicles downregulated genes mediating 
DM1 significantly more than other AD- related with similar NFT 
diseases.
In conclusion, we have studied two different cohorts of DM1 pa-
tients, each one well- matched to a group HCs, and by employing a 
DDS that addresses all the hypothesis- driven preselected genes for 
DM1, DMD, SNCA and MAPT were seen to have a major influence on 
brain damage and ND. Moreover, we found an enrichment of key bi-
ological processes in the CNS, confirmed by a RNA analysis of brain 
samples from DM1 patients, such as synaptic vesicle cycling, recy-
cling and dynamics, and also serotonin and dopamine neurotransmit-
ter signalling. Further studies should clarify whether the interactions 
between DMD, SNCA and MAPT can be generalized to other degen-
erative or developmental conditions, or if these are specific to DM1.
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